This review determined the effectiveness of analgesics for the management of diabetic neuropathy. Head-to-head studies comparing the different analgesics were not performed, thus the authors' conclusions, that tricyclic antidepressants and traditional anticonvulsants are more effective than newer generation anticonvulsants for short-term pain, might be overstated. were searched; the search terms were reported. The authors also checked references from retrieved papers.
Results of the review
were included in the review: 16 parallel design and 9 crossover design. Of these, 17 studies were included in the meta-analysis.
Traditional anticonvulsants.
Efficacy of treatment (3 RCTs, n=111): overall, a beneficial effect of treatment was found compared with placebo (OR 5.33, 95% CI: 1.77, 16.02); there was no evidence of statistical heterogeneity. When categorised by outcome (level of pain relief), there was a beneficial effect of treatment for moderate relief of pain (OR 10.63; 95% CI: 2.25, 50.13) but no difference between groups for a 50% reduction in pain (OR 3.04; 95% CI: 0.88, 10.54).
Withdrawals (4 RCTs, n=181): no between-group difference was found for number of withdrawals related to adverse events for traditional anticonvulsants compared with placebo.
Newer generation anticonvulsants. Efficacy of treatment (4 RCTs, n=623): overall, a beneficial effect of treatment was found compared with placebo (OR 3.25, 95% CI: 2.27, 4.66); there was no evidence of statistical heterogeneity. Categorisation by pain relief (50% reduction or moderate pain relief) did not substantially alter this result.
Withdrawals (5 RCTs, n=811): more withdrawals were found for those treated with newer generation anticonvulsants than those treated with placebo (OR 2.98, 95% CI: 1.75, 5.07).
Antidepressants.
Efficacy of treatment (3 RCTs, n=122): a significant effect in favour of tricyclic antidepressants (TCAs) was found compared with placebo (OR 22.24, 95% CI: 5.83, 84.75) . Categorisation by outcome (notable improvement in global assessment of pain or moderate pain relief) did not substantially alter this result. A beneficial effect of duloxetine (60 mg and 120 mg) was found compared with placebo (OR 2.55, 95% CI: 1.73, 3.77 and OR 2.10, 95% CI: 1.03, 4.27, respectively). A beneficial effect of mexiletine and opioids was also found compared with placebo (weighted mean difference, WMD -1.87, 95% CI: -2.64, -1.11 and OR 4.06, 95% CI: 1.16, 14.21, respectively). No evidence of statistical heterogeneity was found.
Withdrawals: greater numbers of withdrawals due to adverse events of treatment were found for duloxetine 60 mg and 120 mg (OR 2.36, 95% CI: 1.05, and OR 4.65, 95% CI: 2.18, 9.94, respectively) and opioids (OR 4.06, 95% CI: 1. 16, 14.21) . No significant between-group differences in the number of withdrawals due to adverse events for TCAs or mexiletine were found. not state whether this search was limited by language restrictions. The methodology undertaken to extract the data and assess the study quality is likely to have minimised reviewer error or bias. It is not clear how the papers were selected initially, therefore it is not possible to assess whether error or bias could have been introduced at this stage. The quality of the primary studies was assessed and the results reported.
The analyses appeared appropriate; the authors assessed statistical heterogeneity and highlighted some issues with the inclusion of both parallel and crossover design trials. The results of the meta-analyses found that TCAs, traditional anticonvulsants and newer generation anticonvulsants were all effective in pain relief compared with placebo; head-tohead studies comparing the different analgesics were not performed, thus the authors' conclusions that TCAs and traditional anticonvulsants are more effective than newer generation anticonvulsants may be overstated. In addition, despite pooling studies, the results in some instances are based on relatively small sample sizes.
